Property
Our in depth knowledge covers human and animal health markets, medicine and device industries and across the complete life cycle of biotechnology, pharmaceutical and device products. We work closely with our clients to add value and help them to maximise their success, protect against risk and maximise their achievements.
Clients in this industry include start-up companies, venture capital investors, spin off companies, private and publicly listed entities, government, research institutes, leading universities, manufacturers and distributors, international trial sponsors, contract research organisations, collaborative research groups, institutions and principal investigators, biotechnology, medical device and pharmaceutical organisations.
We are the trusted advisors to our clients in this sector, helping them to navigate everything from complex transactions and licensing / collaboration deals to their day to day operational needs to achieve their desired outcome.
Licensing and partnering
The biotech and pharma sector often involves researchers and companies working together to bring discoveries and drugs to the market. When this happens, they require agreements that lay out what all sides have to do. Our lawyers have experience establishing marketing agreements, commercialisation licences, collaboration and research agreements, joint ventures and term sheets, memorandums of understanding and heads of agreement.
Regulatory issues
The biotech and pharma sector is highly regulated. Our team help clients to navigate laws and regulators such as the Therapeutic Goods Administration. We assist on issues such as labelling, approvals for therapeutic and non-therapeutic goods, medical devices and clinical trials.
Capital raising
Our lawyers have extensive experience helping biotech companies to raise funds by listing on the share market through an initial public offering. They can also advise on raising funds through private equity and angel investors, as well as applying for funding grants.
Clinical trials
We advise on the conduct of clinical trials, including sponsorship arrangements, compliance with HREC (human research ethics committee) rules, investigator led trials, and trial participant issues such as privacy.
Intellectual property
Our Intellectual Property team can assist with protecting your valuable intellectual property.
Corporate structuring and collaborations
Thomson Geer's lawyers advise on all aspects of commercial and corporate law and regulation, including structuring and taxation matters. We help clients ensure their company structures are most appropriate for achieving their ultimate goals. We also work with clients to create research collaborations, from study specific through to long term collaborations involving the creation of new medical research institutes.
Cronos Australia
Advising on a merger with CDA Health, one of Australia's largest distributors of medicinal cannabis.
South Australian Health and Medical Research Institute
Assisting with various commercial tasks including its establishment and then advising on clinical trial agreements, fundraising, and privacy law compliance.
QBiotics
Advising on the $130 million merger of the QBiotics Group, by the use of two schemes of arrangement to tophat existing companies, Qbiotics Limited and EcoBiotics Limited, with a new holding company, QBiotics Group Limited.
Microba Life Sciences
Assisted gut health business Microba Life Sciences Ltd on its successful listing on the Australian Securities Exchange in an IPO that raised A$30 million.
Incannex Healthcare
Advising on acquisition of medicinal cannabis research and development company APIRx.
%402x%20(1).svg){kind=icon}
%402x%20(1).svg){kind=icon}
.svg){kind=icon}
Built around principle of quality and value.
Andrew Chalet
Ben Coogan
Bronwyn Furse
Josh Simons
Katrina Chambers
Tony Conaghan
Mark Feetham
Dianne Beer
Dr Peytee Grusche
What's new?
%402x.svg){kind=icon}
About us
Thomson Geer acknowledges the Traditional Custodians of Country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.